Extranodal Lymphoma — Trials

Extranodal Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 18
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: Ruijin Hospital
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02085655	PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma	unknown	Phase 3	264	Huiqiang HuangOTHER	1	Mar 15, 2021	clinicaltrials
NCT00725231	Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14)	unknown	Phase 3	274	University of GöttingenOTHER	1	May 7, 2012	clinicaltrials